
1. oral oncol. 2018 jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. epub 2018
apr 17.

nivolumab vs investigator's choice recurrent metastatic squamous cell
carcinoma head neck: 2-year long-term survival update checkmate 141
with analyses tumor pd-l1 expression.

ferris rl(1), blumenschein g jr(2), fayette j(3), guigay j(4), colevas ad(5),
licitra l(6), harrington kj(7), kasper s(8), vokes ee(9), even c(10), worden
f(11), saba nf(12), docampo lci(13), haddad r(14), rordorf t(15), kiyota n(16),
tahara m(17), lynch m(18), jayaprakash v(18), li l(18), gillison ml(2).

author information: 
(1)university pittsburgh medical center hillman cancer center, pittsburgh, pa,
usa. electronic address: ferrisrl@upmc.edu.
(2)md anderson cancer center, houston, tx, usa.
(3)centre leon berard, lyon, france.
(4)centre antoine lacassagne, fhu oncoage, université côte d'azur, nice, france.
(5)stanford university, stanford, ca, usa.
(6)fondazione irccs istituto nazionale dei tumori university milan, milan,
italy.
(7)royal marsden nhs foundation trust/the institute cancer research national
institute health research biomedical research centre, london, uk.
(8)west german cancer center, university hospital, essen, germany.
(9)university chicago medical center, chicago, il, usa.
(10)gustave roussy, villejuif cedex, france.
(11)university michigan, ann arbor, mi, usa.
(12)winship cancer institute emory university, atlanta, ga, usa.
(13)hospital universitario 12 de octubre, madrid, spain.
(14)dana-farber/harvard cancer center, boston, ma, usa.
(15)universitätsspital zurich, zurich, switzerland.
(16)kobe university hospital, kobe, japan.
(17)national cancer center hospital east, kashiwa, japan.
(18)bristol-myers squibb, princeton, nj, usa.

objectives: report 2-year results checkmate 141 establish the
long-term efficacy safety profile nivolumab outcomes tumor pd-l1
expression patients recurrent metastatic (r/m),platinum-refractory
squamous cell carcinoma head neck (scchn).
methods: patients r/m scchn tumor progression/recurrence within
6 months platinum therapy randomized 2:1 nivolumab 3 mg/kg every
2 weeks investigator's choice (ic). primary endpoint: overall survival (os).
data cutoff: september 2017.
results: 24.2 months' minimum follow-up, nivolumab (n = 240) continued to
improve os vs ic (n = 121), hazard ratio (hr) = 0.68 (95% ci 0.54-0.86).
nivolumab nearly tripled estimated 24-month os rate (16.9%) vs ic (6.0%), and
demonstrated os benefit across patients tumor pd-l1 expression ≥1% (hr [95% 
ci] = 0.55 [0.39-0.78])  < 1% (hr [95% ci] = 0.73 [0.49-1.09]), and
regardless tumor hpv status. estimated os rates 18, 24, 30 months 
nivolumab consistent irrespective pd-l1 expression (<1%/≥1%). the
nivolumab arm, observed differences baseline characteristics 
safety profile long-term survivors overall population. grade 3-4 
treatment-related adverse event rates 15.3% 36.9% nivolumab ic, 
respectively.
conclusion: nivolumab significantly improved os primary analysis and
demonstrated prolonged os benefit vs ic maintenance manageable and
consistent safety profile 2-year follow-up. os benefit observed with
nivolumab irrespective pd-l1 expression hpv status. (clinicaltrials.gov:
nct02105636).

copyright © 2018. published elsevier ltd.

doi: 10.1016/j.oraloncology.2018.04.008 
pmcid: pmc6563923
pmid: 29884413  [indexed medline]

